Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and...
November 14, 2024 09:15 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential...
November 12, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and...
October 30, 2024 08:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference

Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer’s disease...
September 12, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
September 05, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
August 08, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights

Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease that met objectives for tolerability, safety and pharmacokinetics Secured...
August 06, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology

Body of work supports targeting misfolded proteins as a therapeutic strategy for ALS with the potential to translate across multiple neurodegenerative diseases CAMBRIDGE, Massachusetts and TORONTO,...
August 01, 2024 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
July 30, 2024 08:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference

Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer’s disease vaccine CAMBRIDGE,...